Edwards Lifesciences [EW] vs Dexcom [DXCM] Detailed Stock Comparison
Edwards Lifesciences
NYSE
Loading...
Dexcom
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Edwards Lifesciences wins in 14 metrics, Dexcom wins in 5 metrics, with 0 ties. Edwards Lifesciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Edwards Lifesciences | Dexcom | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 32.50 | 56.46 | Edwards Lifesciences |
| Price-to-Book Ratio | 4.33 | 12.22 | Edwards Lifesciences |
| Debt-to-Equity Ratio | 6.62 | 100.24 | Edwards Lifesciences |
| PEG Ratio | 31.71 | 39.49 | Edwards Lifesciences |
| EV/EBITDA | 24.30 | 33.67 | Edwards Lifesciences |
| Profit Margin (TTM) | 72.96% | 13.29% | Edwards Lifesciences |
| Operating Margin (TTM) | 28.12% | 18.37% | Edwards Lifesciences |
| EBITDA Margin (TTM) | 28.12% | 18.37% | Edwards Lifesciences |
| Return on Equity | 15.53% | 22.83% | Dexcom |
| Return on Assets (TTM) | 8.42% | 6.08% | Edwards Lifesciences |
| Free Cash Flow (TTM) | $259.90M | $630.70M | Dexcom |
| 1-Year Return | 13.55% | 8.44% | Edwards Lifesciences |
| Price-to-Sales Ratio (TTM) | 8.02 | 7.31 | Dexcom |
| Enterprise Value | $42.31B | $31.09B | Edwards Lifesciences |
| EV/Revenue Ratio | 7.44 | 7.23 | Dexcom |
| Gross Profit Margin (TTM) | 77.52% | 59.53% | Edwards Lifesciences |
| Revenue per Share (TTM) | $10 | $11 | Dexcom |
| Earnings per Share (Diluted) | $2.39 | $1.42 | Edwards Lifesciences |
| Beta (Stock Volatility) | 1.08 | 1.44 | Edwards Lifesciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Edwards Lifesciences vs Dexcom Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Edwards Lifesciences | 0.10% | -0.11% | 1.89% | 1.80% | 3.42% | 7.81% |
| Dexcom | 1.24% | 2.65% | -4.52% | -5.51% | -10.58% | 3.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Edwards Lifesciences | 13.55% | -20.59% | -0.57% | 235.74% | 706.80% | 2,086.03% |
| Dexcom | 8.44% | -4.89% | -24.15% | 259.78% | 2,494.55% | 2,653.40% |
Performance & Financial Health Analysis: Edwards Lifesciences vs Dexcom
| Metric | EW | DXCM |
|---|---|---|
| Market Information | ||
| Market Cap | $45.61B | $31.44B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 3,552,140 | 5,083,030 |
| 90 Day Avg. Volume | 4,438,990 | 3,546,350 |
| Last Close | $78.26 | $80.95 |
| 52 Week Range | $64.01 - $83.00 | $57.52 - $93.25 |
| % from 52W High | -5.71% | -13.19% |
| All-Time High | $131.73 (Dec 27, 2021) | $164.86 (Nov 15, 2021) |
| % from All-Time High | -40.59% | -50.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.12% | 0.15% |
| Quarterly Earnings Growth | -0.09% | 0.25% |
| Financial Health | ||
| Profit Margin (TTM) | 0.73% | 0.13% |
| Operating Margin (TTM) | 0.28% | 0.18% |
| Return on Equity (TTM) | 0.16% | 0.23% |
| Debt to Equity (MRQ) | 6.62 | 100.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $17.94 | $6.56 |
| Cash per Share (MRQ) | $6.92 | $7.47 |
| Operating Cash Flow (TTM) | $794.90M | $987.70M |
| Levered Free Cash Flow (TTM) | $1.26B | $425.12M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Edwards Lifesciences vs Dexcom
| Metric | EW | DXCM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 32.50 | 56.46 |
| Forward P/E | 31.71 | 39.49 |
| PEG Ratio | 31.71 | 39.49 |
| Price to Sales (TTM) | 8.02 | 7.31 |
| Price to Book (MRQ) | 4.33 | 12.22 |
| Market Capitalization | ||
| Market Capitalization | $45.61B | $31.44B |
| Enterprise Value | $42.31B | $31.09B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.44 | 7.23 |
| Enterprise to EBITDA | 24.30 | 33.67 |
| Risk & Other Metrics | ||
| Beta | 1.08 | 1.44 |
| Book Value per Share (MRQ) | $17.94 | $6.56 |
Financial Statements Comparison: Edwards Lifesciences vs Dexcom
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EW | DXCM |
|---|---|---|
| Revenue/Sales | $1.41B | $1.04B |
| Cost of Goods Sold | $301.60M | $447.00M |
| Gross Profit | $1.11B | $589.00M |
| Research & Development | $254.60M | $145.20M |
| Operating Income (EBIT) | $409.90M | $133.70M |
| EBITDA | $461.60M | $219.00M |
| Pre-Tax Income | $433.90M | $154.30M |
| Income Tax | $70.30M | $48.90M |
| Net Income (Profit) | $356.40M | $105.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EW | DXCM |
|---|---|---|
| Cash & Equivalents | $3.14B | $904.90M |
| Total Current Assets | $6.21B | $4.55B |
| Total Current Liabilities | $1.39B | $3.04B |
| Long-Term Debt | $675.70M | $1.36B |
| Total Shareholders Equity | $10.19B | $2.27B |
| Retained Earnings | $13.53B | $1.70B |
| Property, Plant & Equipment | $1.80B | $59.10M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EW | DXCM |
|---|---|---|
| Operating Cash Flow | $294.00M | $167.90M |
| Capital Expenditures | N/A | $-87.00M |
| Free Cash Flow | $224.40M | $96.80M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-258.60M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | EW | DXCM |
|---|---|---|
| Shares Short | 8.00M | 8.49M |
| Short Ratio | 1.69 | 2.71 |
| Short % of Float | 0.02% | 0.03% |
| Average Daily Volume (10 Day) | 3,552,140 | 5,083,030 |
| Average Daily Volume (90 Day) | 4,438,990 | 3,546,350 |
| Shares Outstanding | 588.60M | 390.70M |
| Float Shares | 581.05M | 389.43M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 0.90% | 0.99% |
Dividend Analysis & Yield Comparison: Edwards Lifesciences vs Dexcom
| Metric | EW | DXCM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |